Current Role of Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non Small Cell Lung Cancer (NSCLC): Which Patients and Why

Ultima Vez Modificado: 15 de octubre del 2004

Share article


Conference Date: December 11, 2004
Conference Location: San Francisco, CA

Conference Date: January 8, 2005
Conference Location: Atlanta, GA

Conference Date: February 5, 2005
Conference Location: Philadelphia, PA

Conference Web Page URL: www.thecbce.com/futureprograms.asp

Topics Covered: This continuing medical education (CME) activity will compare the biology, clinical efficacy, and toxicity of small-molecule EGFR inhibitors in the treatment of NSCLC.

Conference Objectives:

Who Should Attend: This activity is designed primarily for medical oncologists and other physicians interested in the treatment of cancer.

Registration Information: To register, please visit our website at www.thecbce.com/futureprograms.asp or e-mail info@thecbce.com for more information.

Continuing Education: Yes


News
Erlotinib Plus Chemo Doesn't Improve Efficacy in NSCLC

May 3, 2012 - Adding chemotherapy with carboplatin plus paclitaxel to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib does not improve efficacy in the treatment of chemotherapy-naive, never or light former smokers with advanced non-small-cell lung cancer, according to a study published online April 30 in the Journal of Clinical Oncology.



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información